Hikma Pharmaceuticals PLC Overview
Pro stress-test →Hikma Pharmaceuticals specializes in developing, producing, and selling drugs for treating cardiovascular diseases, infections, cancers, diabetes, and other conditions. With TTM revenue of $3.12 billion as of January 2026, the company demonstrates consistent growth with 2024 revenue increasing from $2.87 billion in 2023.
Strategic Profile
Pro stress-test →The company operates across three segments: Branded Pharmaceuticals, Generic Pharmaceuticals, and Injectable Pharmaceuticals. Revenue is driven primarily by generic injectable products (41.8%), oral generics (32.8%), and branded drugs (24.68%), with North America accounting for 61.1% of sales and Middle East/North Africa representing 31.5%.
Competitive Landscape
Pro stress-test →Hikma competes against 30+ pharmaceutical companies including Lupin. The company differentiates through scale in generics, injectables manufacturing footprint, and geographic diversification, particularly in MENA and North America where it has established market presence versus larger global peers.
Industry Context
Hikma Pharmaceuticals PLC operates in Pharmaceuticals - Generics & Specialty.
Key facts
Founded: 1978 · Headquarters: London, UK · Employees: 9,500 · Revenue: $3.12B · Market cap: $3.49B